 The Covid-19 pandemic has caused significant disruptions to cancer care, including delays and cancellations in treatment, screening and diagnosis, as well as psychological and financial stressors. While some countries have seen improvements in access to care through telemedicine, more research is needed to determine its effectiveness and cost-effectiveness. Additionally, the long-term effects of these disruptions on cancer outcomes remain unclear. This article was authored by Tallent Muka, Joshua J. X. Lee, Sahar J. Farani, and others.